Kornimate/medical-research-clean huggingface dataset:
eating chocolate at the right time benefits the circadiam sytem and metabolic efficiency.

Conditions: Menopause

Summary: the purpose of this investigation is to test the hypothesis that in humans, eating a relatively big amount of chocolate at the wrong time (bedtime) may disrupt our circadian system (change the circadian phase), while taking this same amount of chocolate in the morning (wake up condition) may synchronize it. other related factors may be also affected such as total body weight and body fat, dietary habits (total energy intake and macronutrient distribution), the timing of food intake and of sleep, daily rhythms of tap, microflora composition and postprandial glycemia.

recent studies suggest that not only "what" the people eat, but also "when" the people eat may have a significant role in obesity treatment and in the regulation of the circadian system. thus, the hypothesis of this study is eating a relatively big amount of chocolate at the wrong time, bedtime may affect: 1. metabolism: resting energy expenditure, corrected resting energy respiratory quotient (rq) 2. glucose metabolism 3. total weight loss 4. food intake, total energy intake, and type of food 5. microflora (feces) 6. mood 7. disrupt our circadian system 7a) changes in temperature, actimetry, and position 7b) electrocardiogram (ecg) 7c) melatonin (two points) cortisol rhythm (three points) while having this same amount of chocolate in the morning (wake up condition) may synchronize it. other related factors may be also affected such as total body weight and body fat, dietary habits (total energy intake and macronutrient distribution), the timing of food intake and of sleep, daily rhythms of tap, microflora composition and postprandial glycemia. 19 women (postmenopausal) following the habitual dietary habits of participants (ad libitum) will have 30% of the habitual total daily calories in chocolate of participants (nestle, "chocolate with milk") during two consecutive weeks each under three conditions: eating chocolate within 1 hour of habitual wake-time, eating chocolate within 1 hours of habitual bedtime, or eating no chocolate. no other chocolate (i.e., none at all in control and in the washout weeks). the protocol will be a randomized, cross-over design, with a 1-week washout between each condition. during the 14 days in each condition, the participants will record sleep and activity schedules by dairy, food intake and food timing by phone application, daily rhythms of wrist temperature, activity and position (tap).

Eligibility criteria:
inclusion criteria: * healthy women * age: between 45 and 65 year of age * caucasian * menopause exclusion criteria: * pre-menopause women * endocrine (diabetes mellitus or others), renal, hepatic, cancer or psychiatric disorders * receiving any pharmacologic treatment other than oral contraceptives * bulimia diagnosis, prone to binge eating * pregnancy

Keywords: chocolate timing menopause calorimetry
comparison of couple-based ptsd treatment and couple-based ptsd education

Conditions: Stress Disorders, Post-Traumatic

Summary: the study is designed to evaluate the efficacy of a novel couple-based treatment for ptsd, called structured approach therapy, to decrease ptsd and improve the marital and social functioning of iraqi war veterans and their partners. the effectiveness of couples therapy will be compared with the effectiveness of a couple-based educational intervention.

the goal of the proposed study is to test the efficacy of a novel couple-based ptsd treatment, called structured approach therapy, by randomly assigning 57 iraqi war veterans and their partners to either a 12-15 session structured approach therapy program, or to a 12-15 session ptsd family education comparison condition. the efficacy of the two experimental conditions will be ascertained by obtaining measures of ptsd severity from veterans and measures of relationship functioning and emotion regulation from veterans and their partners prior to treatment, immediately after treatment, and three months after the last treatment session. the investigators will test the hypothesis that couples participating in structured approach therapy will show significantly greater improvements on all three clinical outcome measures than couples participating in ptsd family education. these hypotheses will be tested with an intent-to-treat analysis using general linear mixed models with main effects of treatment, time (baseline, end of treatment, and 12 week follow-up), and treatment by time interactions to model the longitudinal trajectories of the outcome, separately for the veterans and their partners. the objectives of the structured approach therapy intervention are to decrease ptsd severity, improve relationship and family functioning, and decrease problems in emotion regulation in a group of young veterans at risk for developing chronic ptsd, and to reduce emotional distress and relationship and family problems in their partners.

Eligibility criteria:
inclusion criteria: * exposure to at least one combat-related stressful event during combat deployment, * current diagnostic criteria for ptsd for that event, and * veteran is in a committed relationship and living with an opposite sex partner for at least six months. exclusion criteria: * current psychotic symptoms in either partner, * current diagnosis of alcohol or drug dependence in either partner, * history of recent physical assault/abuse, * currently receiving an evidence-based ptsd treatment (exposure-based or cognitive processing therapy) * currently receiving couples therapy or family therapy

Keywords: couples therapy ptsd
a study of ro5186582 in down syndrome among children 6 to 11 years of age

Conditions: Down Syndrome

Summary: this study will evaluate the safety, tolerability, efficacy, and pharmacokinetic and pharmacodynamic activity of 3 different dosages of ro5186582 compared with placebo. a total of approximately 46 participants will be enrolled, in order to have at least 32 evaluable, and will be randomly assigned to 1 of 4 treatments in a 1:1:1:1 ratio, with 9 children per treatment arm. the target ratio between 6-8 years and 9-11 years age groups is approximately 1:1 in each treatment arm, with a minimum of 3 children per age group in each treatment arm.


Eligibility criteria:
inclusion criteria: * diagnosis of down syndrome, except for mosaic down syndrome * available parent or caregiver to attend clinic visits and provide information about the participant's behavior and symptoms exclusion criteria: * any primary psychiatric comorbid disorder * history of infantile spasms, west syndrome, lennox-gastaut syndrome, early infantile epileptic encephalopathy, treatment-refractory epilepsy with cognitive/developmental regression, severe head trauma, or central nervous system (cns) infection * seizure event of any type within 12 months prior to screening or relevant changes in anti-epileptic drugs 6 weeks prior to enrollment * significant sleep disruption * significant gastrointestinal, renal, hepatic, endocrine, or cardiovascular disease * new-onset or ongoing hematologic/oncologic disorder * severe lactose intolerance * participation in another clinical study within 1 month or 6 half-lives prior to first dose, or any extent of participation in study bp29589 (nct02451657)
treatment of severe infections with mesenchymal stem cells

Conditions: Septic Shock

Summary: the main purpose at the early phase of septic shock on the evolution of organ failure judged by the sofa (sepsis organ failure assessment score) score on day 7 (or the day of death or the day of discharge from the intensive care unit if before day 7) compared to sofa score observed in patients in the control group. the secondary purpose is to assess the role of heterologous mesenchymal stem cells on the occurrence and duration of failure of each organ and on the mortality at day 28 and day 90. the safety of administration will be also assessed.

patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 10\^6/kg heterologous mesenchymal stem cells in 250 ml albumin 4%, infused for 30 minutes in central venous line or 250 ml albumin 4% alone.

Eligibility criteria:
inclusion criteria: * septic shock of community origin since less than 12 hours. the onset time of septic shock is the time of catecholamine introduction( adrenaline, noradrenaline, or dopamine \> 8μg/kg/min) * at least 2 organ failure other than hemodynamic * occurrence between monday 8am and friday 8am (for availability reasons of staff) * signature of informed consent (patient/close relative or reliable person) * affiliation to social security plan exclusion criteria: * non-septic shock * nosocomial septic shock * pao2/fio2 \<100 * pregnant or breast-feeding woman * brain death * dying person * therapeutic limitations * participation to another current interventional clinical trial or since less than 30 days
rfviiifc (elocta®) iti chart review in patients with haemophilia a

Conditions: Hemophilia A With Inhibitor

Summary: a chart review study of patients with haemophilia a with inhibitors treated with rfviiifc (elocta®) for immune tolerance induction.

a multicenter, international, non- interventional, retrospective and prospective medical chart review study. data will be collected from medical records for patients diagnosed with haemophilia a who have been, or who are currently, treated with rfviiifc for iti . the study will be descriptive in nature and report on baseline characteristics, treatment and outcomes for patients who have been, or who are currently, treated with rfviiifc for iti.

Eligibility criteria:
inclusion criteria: * patients diagnosed with haemophilia a who have been, or who are currently, treated with rfviiifc for iti. * signed and dated informed consent provided by the patient, or the patient's legally acceptable representative for patients under the legal age, before any study-related data collection are undertaken. assent should be obtained from paediatric patients according to local regulations. exclusion criteria: * current participation in any investigational medicinal product trial.

Keywords: elocta rfviiifc
postpartum hemorrhage: incidence and risk factors

Conditions: Postpartum Hemorrhage

Summary: postpartum hemorrhage(pph) is a major cause of maternal morbidity and mortality across the world. incidence of pph varies in the literature from 2 to 10%, most recent studies find around 10% of pph and 2% of severe pph. in this study, the incidence of pph in the maternal ward of the chu brugmann will be analyzed. this is a tertiary maternal ward with a high proportion of high risk pregnancies with around 3000 admissions per year. primary aim of this study is to evaluate the epidemiology of pph in the chu brugmann, incidence and possible underlying causes will be identified and compared to the current literature. a data mining technique will be used to construct a prediction model for pph.


Eligibility criteria:
inclusion criteria: * pregnant women who have given birth vaginally or by cesarean section at the chu brugmann between january 1, 2020 and august 31, 2022 * ≥ 18 years exclusion criteria: * age ≤ 18 years * age \> 60 years * delivery before 25th week of pregnancy * delivery outside of the hospital * abortion
refractive error in chinese students

Conditions: Myopia

Summary: this cohort study aimed to assess the change of refractive status in chinese school children.

a cohort study was conducted in 96 primary and secondary schools in 16 districts of tianjin from 2018 to 2020, including about 36452 people totally. the changes in myopia rate in 3 years were compared by a generalized estimation equation. the distribution of average equivalent spherical mirror and different regions and grades was evaluated by linear regression analysis, and the correlation between the equivalent spherical mirror and different gender, nationality, and age was evaluated.

Eligibility criteria:
inclusion criteria: * no concurrent eye disease * age from 6 to 18 years old exclusion criteria: * significant systemic illnesses * ocular conditions * congenital corneal diseases * pterygium, keratoconus * corneal degeneration or dystrophy * media opacity, uveitis, glaucoma * history of ocular surgery * neurologic diseases * retinal disease.

Keywords: covid-19 refractive error china myopia
nocturnal pain after knee arthroplasty : incidence and risk factor: an observational study

Conditions: Knee Osteoarthritis; Pain, Postoperative; Prosthesis (Internal) Complications; Nocturnal Frequency

Summary: in prosthetic knee surgery, there is a certain number of patients with post-operative nocturnal pain. the purpose of our study is to determine the impact of this problem and to better understand its risk factors.

in prosthetic knee surgery, there is a certain number of patients with post-operative nocturnal pain. the purpose of our study is to determine the impact of this problem and to better understand its risk factors. this is a poorly studied issue and the study could better detect, evaluate and treat painful patients after knee replacement surgery.

Eligibility criteria:
inclusion criteria: * undergoing elective primary total knee arthroplasty or unicompartmental knee arthroplasty due to knee joint osteoarthritis * older than 18 years * willing and able to complete pre and postoperative surveys exclusion criteria: * history of drug abuse * previous knee arthroplasty * mental disorders * rheumatoid arthritis * chronic renal disease * chronic hematological diseases (sickle cell disease, haemochromatosis...)
opioid titration with 12.5 ug/h fentanyl transdermal patch vs orally morphine for opioid-naïve patients with moderate cancer pain

Conditions: Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive

Summary: opioid is recommended for moderate cancer pain in who 3-step analgesic ladder. transdermal administration of the strong opioid fentanyl was originally developed for patients unable to swallow analgesics because of malignancies in the head and neck region or the gastrointestinal tract, painful lesions in the mouth, or periods of nausea, vomiting, or bowel obstruction. the ema recognizes that in exceptional clinical circumstances, the 12 μg/h fentanyl patch could be considered. to our knowledge, there is not a phase iii trial to explore the efficacy and safety of 12 μg/h fentanyl patch in opioid-naive patients with moderate cancer pain.


Eligibility criteria:
inclusion criteria: 1. age 18 years old or more; 2. ecog ps ≤3 ; 3. opioid tolerance not moderate pain patients (4≤ nrs ≤6 on 11 points, 0 no pain, 10 most pain); 4. no taking strong opioids for the last 30 days; 5. estimated life expectancy of at least 3 months; 6. ability to communicate effectively with the study personnel about the nature of their pain; 7. ability to complete a diary; 8. cancer pain is expected to be relatively stable and last for more than 48 hours; 9. the patient understands the research process, agrees to participate in the trial, cooperates with the treatment and visit plan, and signs an informed consent form. exclusion criteria: 1. known allergy to any ingredient in both fentanyl and morphine; 2. no cancer associated pain or the pain of unknown cause, such as osteoarthritis pain, acute abdominal pain; 3. primary tumors or metastases in the brain; 4. an active skin disease that precluded application of the transdermal system; 5. anti-cancer therapy (radiotherapy, chemotherapy, targeted therapy, etc.) is used during the study period, and the treatment has an impact on the analgesic effect or adverse reactions of analgesic drugs; 6. no bowel movement within 3 days before the screening period; 7. the patient has contraindications to the use of opioids: such as respiratory depression; head damage; paralytic intestinal obstruction; acute abdomen; chronic obstructive airway disease; pulmonary heart disease; chronic bronchial asthma; hypercapnia; 8. used monoamine oxidase inhibitor within 1 week before randomization; 9. any abnormal laboratory test results with obvious clinical significance, such as creatinine value ≥ 2 times the high limit of the normal value or alt or ast ≥ 2.5 times the high limit of the normal value (for patients with liver metastases can be relaxed to ≥ 5 times the high limit of the normal value) ; 10. patients with a history of drug abuse; 11. patients with mental illness or cognitive impairment; 12. pregnant or lactating women; subjects who have a pregnancy plan within 1 month after the test (including male subjects); 13. participate in the drug trial (including the trial drug) within 3 months before the trial.
effect of oxytocin infusion on blood loss during abdominal myomectomy

Conditions: Myomectomy

Summary: to evaluate the effects of oxytocin infusion during abdominal myomectomy.

myomectomy is indicated for symptomatic uterine fibroids. fibroids have blood supply and 20% of the abdominal myomectomy cases might require blood transfusion because of the nature of the surgery. oxytocin infusion is one of the intervention to decrease blood loss during myomectomy. to evaluate the effects and benefits of oxytocin infusion during abdominal myomectomy we decide to conduct this randomized study.

Eligibility criteria:
inclusion criteria: * age 18-50 * patients who are candidate for abdominal myomectomy exclusion criteria: * history of previous myomectomy. * suspected malignancy * patients with preoperative anemia * patients using hormonal treatments before the surgery.

Keywords: myomectomy oxytocin blood loss
the effects of remimazolam on the incidence of hypoxia during sedated hysteroscopy for assisted reproduction in overweight or obese patients

Conditions: Hypoxia; Hysteroscopy; Overweight or Obesity

Summary: hypoxia is a common adverse event during sedated hysteroscopy for assisted reproduction, and it is more likely to occur in overweight or obese patients. in sedated gastroscopy, the incidence of hypoxia with remimazolam is lower than that with propofol. the present study is a single-center, randomized, single-blind, controlled clinical trial. overweight or obese patients undergoing sedated hysteroscopy for diagnosis and treatment, with asa grade i or ii, were selected as subjects and randomly divided into an experimental group and a control group, with 300 subjects in each group. sedation induction and maintenance are performed using remimazolam or propofol combined with remifentanil, respectively, to compare the incidence of hypoxia during surgery between the two groups of patients.


Eligibility criteria:
inclusion criteria: 1. age between 20 and 50 years. 2. patients undergoing sedated hysteroscopy for assisted reproduction. 3. asa classification i-ii. 4. bmi ≥ 23 kg/㎡. 5. patients who have signed an informed consent form. exclusion criteria: 1. spo2 \< 95% in patients inhaling air upon entering the room. 2. diagnosed with chronic obstructive pulmonary disease (copd) or currently suffering from other acute and chronic lung diseases requiring long-term or intermittent oxygen therapy. 3. patients with a history of mental and neurological disorders: such as depression, severe central nervous system depression, parkinson's disease, basal ganglia disease, schizophrenia, epilepsy, alzheimer's disease, myasthenia gravis, etc. 4. patients with severe liver dysfunction. 5. patients with severe renal insufficiency (requiring dialysis before surgery). 6. severe heart failure (mets \< 4). 7. history of drug abuse and/or alcohol abuse within the 2 years preceding the screening period (consuming more than three times the standard alcoholic beverages daily, approximately 10g of alcohol, or equivalent to 50g of chinese alcohol). 8. allergies or contraindications to benzodiazepines, flumazenil, opiates and their rescue medications, propofol, eggs, or soy products. 9. breastfeeding women. 10. patients whom investigator believe are unsuitable for participating in this trial.

Keywords: hypoxia hysteroscopy overweight or obesity remimazolam propofol
role of us in evaluation of tendon and ligament abnormalities in hand and fingers

Conditions: Tendon Disorder

Summary: assessment of the role of usg in the evaluation of tendon and ligament abnormalities in hand and fingers in traumatic \& non-traumatic causes.

the hand and fingers are the most important functional parts of the body in daily life activities and are prone to traumatic injuries and susceptible to a wide array of inflammatory diseases. tendon abnormalities of the hand and the fingers are common disorders, particularly among athletes and in the elderly. these abnormalities may be symptomatic degenerative changes, inflammatory, or rupture. tendon disorders are a common cause of pain and loss of function. chronic tendon disorders are much more common than acute injuries and are the result of overuse or age-related tendon degeneration. there is a wide spectrum of hand and finger pathological conditions that can be demonstrated using ultrasonography. superficial structures of the wrist, hand, and fingers, including the tendons, ligaments, nerves, and vessels, are amenable to imaging with high-frequency us. us can depict masses and fluid collections, help locate radiolucent foreign bodies, characterize traumatic or overuse tendon or ligament pathology, and help evaluate compressive peripheral neuropathy and microvascular blood flow. additionally, this modality improves the accuracy of therapeutic intra-articular or peritendinous injections and facilitates aspiration of fluid collections, such as ganglia. due to the improvement of imaging techniques in the last years, the performance of ultrasonography (us) in detecting pathological changes in the musculoskeletal system dramatically increased. moreover, dynamic examination allows better evaluation of the type and extension of the lesions. an anatomical course of the nerves and tendons can be depicted by us, thus offering valuable information on the exact location and type of possible lesions. the role of usg in the assessment of tendon disorders is steadily increasing due to its being low cost, fast, wide-spread availability, and non-invasive. additionally, it may offer a dynamic assessment of the flexor and extensor tendons, collateral ligaments, and supporting structures of the fingers, such as the extensor hood and the volar plate, as well as space-occupying lesions. the quality of usg assessment of anatomical structures in the hand has highly improved over the last time. the development of high resolution with the highest possible frequency of modern ultrasound equipment and the superficial location of most tendons allows the spectrum of tendon abnormalities to be easily depicted with usg. us facilitates dynamic, real-time evaluation of bones, joints, tendons, nerves, and vessels, making it an ideal imaging modality for hand and finger conditions.

Eligibility criteria:
inclusion criteria: * patients complaining of pain or masses of the hands and the fingers or referred for assessment of tendon \& ligaments which are involved in such pain and swellings. exclusion criteria: * patients with a recent history of local operative intervention will be excluded